Ralinepag
Pulmonary Arterial Hypertension
Phase 3Active
Key Facts
About United Therapeutics
United Therapeutics Corporation is a biotechnology company dedicated to developing life-saving medicines for patients with rare diseases, particularly pulmonary arterial hypertension. Founded in 1996 by Dr. Martine Rothblatt, the company has successfully commercialized multiple breakthrough therapies and continues to advance innovative treatment approaches including gene therapy and xenotransplantation. With a strong financial position and diversified product portfolio, United Therapeutics is well-positioned to maintain its leadership in rare disease therapeutics.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK3640254 | GSK plc | Phase 2 |
| PAH Program | Insmed | Phase 2b |
| Treprostinil (Remodulin) | United Therapeutics | Commercial |
| Treprostinil (Orenitram) | United Therapeutics | Commercial |
| Selexipag (Uptravi) | United Therapeutics | Commercial |
| Orenitram® | Supernus Pharmaceuticals | Approved/Commercial |
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |